| Literature DB >> 34388408 |
Andrée Boucher1, Shereen Ezzat2, Sebastien Hotte3, Irina Rachinsky4, Murali Rajaraman5, Dean Ruether6, Sam M Wiseman7, James Brierley8, Cheryl Ho9, Monika Krzyzanowska2, Nathan Lamond10, Marie-Hélène Massicotte11, Shereen Joseph12, Kassey Herscovitch12, Lindsey Sikora13, Eric Winquist14.
Abstract
Radioactive iodine-resistant differentiated thyroid cancer (RAIRTC) is an aggressive form of thyroid cancer that is uncommon and heterogeneous in its clinical behavior. With the emergence of more effective systemic therapy, the need for guidance in decision-making was recognized and a consensus committee of national experts was assembled. The consensus committee consisted of 13 clinicians involved in treating RAIRTC from across Canada and included endocrinologists, nuclear medicine physicians, surgeons, and radiation and medical oncologists. Domains of interest were identified by consensus, and evidence gathered using systematic reviews. Consensus recommendations for the diagnosis and management of RAIRTC were developed. It was recognized that the rarity of RAIRTC in practice and heterogeneous patterns of thyroid cancer care could limit access to effective therapy for some RAIRTC patients. This document offers guidance to manage RAIRTC patients in a multidisciplinary manner.Entities:
Keywords: Differentiated thyroid cancer; Head and Neck Neoplasms; Iodine Radioisotopes; Lenvatinib; Protein Kinase Inhibitors; Radioactive iodine; Refractory; Resistant; Sorafenib; Thyroid Neoplasms
Mesh：
Substances：
Year: 2021 PMID： 34388408 DOI： 10.1016/j.oraloncology.2021.105477
Source DB: PubMed Journal: Oral Oncol ISSN： 1368-8375 Impact factor: 5.337